[건강레이더] Korea’s No. 1 corona treatment, expected to be put on site early next month

It is expected that the first Korean Corona 19 treatment can be used in the field early next month.

At a meeting of the Central Disaster and Safety Countermeasures Headquarters held at the Seoul Government Complex on the 18th, Prime Minister Jeong Sye-gyun said, “If the remaining screening procedures proceed without any problems, quarantine from the beginning of next month,” about Celltrion’s No. 1 antibody treatment. We expect to be put into the field and serve as a reassuring support force,” he said.

Prime Minister Chung urged, “The Ministry of Food and Drug Safety must conduct a rigorous review according to scientific standards, but quickly draw a conclusion.”

The Ministry of Food and Drug Safety held a meeting of the’Corona 19 Treatment and Vaccine Safety and Effectiveness Verification Advisory Group’ meeting on the 17th, verified the results of the clinical trials of Rekkirona, and disclosed the contents on the day.

The advisory group confirmed that patients who received 40 mg of Rekirona per 1 kg of body weight recovered from symptoms after 5.34 days, and after 8.77 days of placebo, and patients who received this drug recovered quickly by about 3.43 days.

The advisory group determined that the reduction in the time for improvement of Corona 19 symptoms with the administration of this drug was statistically significant and clinically significant. There were no significant side effects.

Accordingly, the advisory group recommended that the product be approved on the premise of conducting phase 3 clinical trials.

Based on this advisory group meeting, the Ministry of Food and Drug Safety is planning to review the submitted materials such as some quality data that are still remaining, synthesize the results, and receive advice from the’Central Pharmacy Review Committee’, the legal advisory body of the Ministry of Food and Drug Safety.

Celltrion explained that, as a result of administering Rekirona to mild and moderate Corona 19 patients, the recovery period was reduced by more than 3 days and the incidence of severe patients was reduced by 54%.

Reporter Kwon Ohyong [email protected]